NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News, & Analysis

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Monday, August, 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.09. The biotechnology company earned $81.10 million during the quarter, compared to analysts' expectations of $82.61 million. Ironwood Pharmaceuticals had a negative net margin of 34.03% and a negative return on equity of 2,073.20%. The business's revenue for the quarter was up 24.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.28) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

8 brokerages have issued 12 month price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $19.1111 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 15,985,637 shares, a decline of 8.2% from the July 13th total of 17,413,293 shares. Based on an average daily trading volume, of 1,067,452 shares, the days-to-cover ratio is presently 15.0 days. Approximately 10.6% of the shares of the company are sold short. View Ironwood Pharmaceuticals' Current Options Chain.

Some companies that are related to Ironwood Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and Catalent (CTLT).

News stories about IRWD stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news and rumor sentiment score of 0.14 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 49.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (11.91%), Janus Henderson Group PLC (5.31%), OppenheimerFunds Inc. (1.88%), Point72 Asset Management L.P. (0.71%), Schwab Charles Investment Management Inc. (0.48%) and Bank of New York Mellon Corp (0.41%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Sector Gamma AS, Broderick Brian C, State of Wisconsin Investment Board, Janus Henderson Group PLC, Fisher Asset Management LLC, Alps Advisors Inc., Los Angeles Capital Management & Equity Research Inc. and Platinum Investment Management Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, OppenheimerFunds Inc., Mizuho Securities USA LLC, First Republic Investment Management Inc., Nomura Holdings Inc., Millennium Management LLC and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $18.28.

Ironwood Pharmaceuticals has a market capitalization of $2.88 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]